

Entecavir- Drug Insight and Market Forecast – 2030

<https://marketpublishers.com/r/E731F5022708EN.html>

Date: October 2020

Pages: 50

Price: US\$ 2,750.00 (Single User License)

ID: E731F5022708EN

Abstracts

This report can be delivered to the clients within 24 Hours

“Entecavir- Drug Insight and Market Forecast – 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Entecavir in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary

Entecavir, sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus infection. In those with both HIV/AIDS and HBV antiretroviral medication should also be used. Entecavir is taken by mouth as a tablet or solution.

Scope of the report

The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and

adverse reactions.

Elaborated details on regulatory milestones and other development activities have been provided in this report.

The report also highlights the drug marketed details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Entecavir.

The report contains historical and forecasted sales for Entecavir till 2030.

Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

The report also features the SWOT analysis with analyst insights and key findings of Entecavir.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Entecavir Analytical Perspective by DelveInsight

In-depth Entecavir Market Assessment

This report provides a detailed market assessment of Entecavir in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Entecavir Clinical Assessment

The report provides the clinical trials information of Entecavir covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

In the coming years, the market scenario for Entecavir is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence Entecavir dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Other approved products for the disease are giving market competition to Entecavir and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Entecavir.

Our in-depth analysis of the sales data of Entecavir from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Entecavir in the market.

Key Questions

What is the prescribed dosage and strengths of Entecavir available in the market?

What are the common adverse reactions or side effects of Entecavir?

What is the product type, route of administration and mechanism of action of

Entecavir?

What are the chemical specifications of Entecavir?

How are the clinical trials diversified on the basis of the trial status?

What is the history of Entecavir, and what is its future?

What are the marketed details of Entecavir in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

How many patents have been granted to Entecavir and when these patents will get expire?

What are the pros (benefits) and cons (disadvantages) of Entecavir?

In which countries Entecavir got approval and when it gets launched?

What are the clinical trials are currently ongoing for Entecavir?

How the safety and efficacy results determined the approval of Entecavir?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Entecavir development?

What are the key designations that have been granted to Entecavir?

What is the historical and forecasted market scenario of Entecavir?

How is the market trend of Entecavir is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?

What are the other approved products available and how these are giving competition to Entecavir?

Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Contents

1. PRODUCT OVERVIEW

- 1.1. Indication
- 1.2. Mechanism of Action
- 1.3. Dosage and Administration
 - 1.4.1 Dosage Forms and Strengths
- 1.4. Route of Synthesis
- 1.5. Pharmacology
 - 1.4.2 Pharmacodynamics
 - 1.4.3 Pharmacokinetics
- 1.6. Adverse Reactions
- 1.7. Product Snapshot
- 1.8. Development Milestones of Entecavir
- 1.9. Marketed Details
 - 1.4.4 United States
 - 1.4.5 Europe
 - 1.4.6 Japan
- 1.10. Patent Details

2. SWOT ANALYSIS

- 2.1. Analyst Views

3. REGULATORY MILESTONES

- 3.1. Approvals
- 3.2. Research and Development
- 3.3. Clinical Trials Information
- 3.4. Safety and Efficacy
- 3.5. Product Developmental Activities

4. MARKET ASSESSMENT

- 4.1. 7MM Market Analysis
- 4.2. United States
- 4.3. Europe
- 4.4. Japan

4.5. Key Findings

5. MARKET COMPETITORS

6. EMERGING THERAPIES

7. APPENDIX

7.1. Report Purchase Options

List Of Tables

LIST OF TABLES

Table 1 Entecavir, Description

Table 2 Entecavir, Trial Diversification

Table 3 Entecavir, Marketed Details United States

Table 4 Entecavir, Marketed Details Europe

Table 5 Entecavir, Marketed Details Japan

Table 6 Patent Details: Entecavir

Table 7 Entecavir, Clinical Trial Description, 2020

Table 8 Safety and Efficacy Results for Entecavir

Table 9 Entecavir, 7MM Market Size from 2017 to 2030 (in Million USD)

Table 10 Entecavir, US Market Size from 2017 to 2030 (in Million USD)

Table 11 Entecavir, EU Market Size from 2017 to 2030 (in Million USD)

Table 12 Entecavir, EU5 Market Size from 2017 to 2030 (in Millions USD)

Table 13 Entecavir, Japan Market Size from 2017 to 2030 (in Million USD)

Table 14 Market Competitors

Table 15 Emerging Therapies

List Of Figures

LIST OF FIGURES

Figure 1 The Development Timeline of Entecavir

Figure 2 Patent Details, Entecavir

Figure 3 Entecavir, 7MM Market Size from 2017 to 2030 (in Million USD)

Figure 4 Entecavir, US Market Size from 2017 to 2030 (in Millions USD)

Figure 5 Entecavir, EU Market Size from 2017 to 2030 (in Millions USD)

Figure 6 Entecavir, EU5 Market Size from 2017 to 2030 (in Millions USD)

Figure 7 Entecavir, Japan Market Size from 2017 to 2030 (in Millions USD)

I would like to order

Product name: Entecavir- Drug Insight and Market Forecast – 2030

Product link: <https://marketpublishers.com/r/E731F5022708EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E731F5022708EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970